Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Portella

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
International Journal of Dermatology|August 1, 1991
Lyme diseaseA L Filgueira, R A Florião, O Portella, et al.
Blood|October 19, 2017
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND studyRaymond S M Wong, Mansoor N Saleh, Abderrahim Khelif, et al.
Blood|October 12, 2018
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopeniaMichael Dickinson, Honar Cherif, Pierre Fenaux, et al.
Journal of Comparative Effectiveness Research|March 17, 2020
Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonistsAnna Forsythe, John Schneider, Timothy Pham, et al.
American Journal of Hematology|November 13, 2018
Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND studyAbderrahim Khelif, Mansoor N Saleh, Abdulgabar Salama, et al.
The Lancet. Haematology|December 16, 2017
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trialMoshe Mittelman, Uwe Platzbecker, Boris Afanasyev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trialPaulo M Hoff, Daniel F Saragiotto, Carlos H Barrios, et al.
Phytochemistry|September 7, 2021
Evidence of altitudinal gradient modifying genomic and chemical diversity in populations of Lychnophora pinaster MartRoberto O Portella, Erick M G Cordeiro, Ana Paula S Marques, et al.
Haematologica|May 3, 2008
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myelomaVania T M Hungria, Angelo Maiolino, Gracia Martinez, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Journal of Dermatology|August 1, 1991
Lyme diseaseA L Filgueira, R A Florião, O Portella, et al.
Blood|October 19, 2017
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND studyRaymond S M Wong, Mansoor N Saleh, Abderrahim Khelif, et al.
Blood|October 12, 2018
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopeniaMichael Dickinson, Honar Cherif, Pierre Fenaux, et al.
Journal of Comparative Effectiveness Research|March 17, 2020
Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonistsAnna Forsythe, John Schneider, Timothy Pham, et al.
American Journal of Hematology|November 13, 2018
Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND studyAbderrahim Khelif, Mansoor N Saleh, Abdulgabar Salama, et al.
The Lancet. Haematology|December 16, 2017
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trialMoshe Mittelman, Uwe Platzbecker, Boris Afanasyev, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trialPaulo M Hoff, Daniel F Saragiotto, Carlos H Barrios, et al.
Phytochemistry|September 7, 2021
Evidence of altitudinal gradient modifying genomic and chemical diversity in populations of Lychnophora pinaster MartRoberto O Portella, Erick M G Cordeiro, Ana Paula S Marques, et al.
Haematologica|May 3, 2008
Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myelomaVania T M Hungria, Angelo Maiolino, Gracia Martinez, et al.
Pageof 1